Anna Boguszewska-Czubara

Prof. Anna Boguszewska-Czubara


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in European Journal of Cell Biology
Verified
Journal Article
Open access
DKDanuta Krasowska
Danuta Krasowska
AMAleksandra Mordzińska-Rak
Aleksandra Mordzińska-Rak
AOAdrian Odrzywolski
Adrian Odrzywolski
EBEwa Błaszczak
Ewa Błaszczak
AMAgata Małek
Agata Małek
ABAnna Boguszewska-Czubara
Anna Boguszewska-Czubara
Epidemiological and clinical studies show a clear association between melanoma, a highly aggressive form of skin cancer, and a neurodegenerative disorder-Parkinson's disease (PD). Patients with PD have a higher risk of developing melanoma and vice versa, although the precise mechanisms underlying this relationship remain poorly understood. Drugs commonly used in Parkinson's disease treatment, including amantadine, rasagiline and carbidopa (C-DOPA), have gained attention for their potential anticancer properties. However, the evidence supporting this requires further research. Here, we used a zebrafish (Danio rerio) as a model system, due to its rapid development and transparency, to study the effect of the aforementioned drugs in vivo. We determined the lethal concentration (LC50) of the drugs tested. Rasagiline exhibited an LC50 three times higher than that of amantadine and C-DOPA. We also established a zebrafish embryonic human melanoma xenograft model using the SK-MEL-28, FM-55-P, and FM-55-M2 melanoma cell lines. The impact on melanoma cells in a zebrafish xenograft model was comparable to the control for rasagiline and C-DOPA, suggesting limited efficacy against melanoma in this context. Amantadine demonstrated modest dose-dependent effects with a significant decrease in proliferation at higher doses. While these drugs were not expected to have strong anticancer effects, the findings support their safety profile in this context. Our bioinformatics analysis showed molecular associations between the two diseases but also studied drug targets. Further development and investigation are needed to explore the potential effects of PD drugs on human melanoma and to better understand the complex association between both diseases. The use of zebrafish as a xenotransplantation model offers great opportunities to investigate such drugs and their effects on melanoma cells in a living organism.

8 November 2026 in Cells
Verified
Journal Article
Open access
PDF file
EOEstera Okoń
Estera Okoń
AJAgata Jarząb
Agata Jarząb
Wirginia Kukula-KochWirginia Kukula-Koch
Wirginia Kukula-Koch
JTJoanna Tokarczyk
Joanna Tokarczyk
Wojciech KochWojciech Koch
Wojciech Koch
AWAnna Wawruszak
Anna Wawruszak
Epigenetic dysregulation constitutes a fundamental molecular hallmark of oncogenesis, arising from aberrant alterations in chromatin architecture and transcriptional regulation that disrupt cellular differentiation, sustain malignant phenotypes, promote therapeutic resistance, and facilitate tumor initiation and progression. Among the principal epigenetic mechanisms, histone acetylation is dynamically regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), making these enzymes attractive targets for pharmacological intervention. Although several synthetic epigenetic drugs have entered clinical practice, their therapeutic utility may be constrained by limited selectivity, toxicity, and adaptive resistance, prompting the continued investigation of structurally diverse natural compounds. The review examines comparatively underexplored plant-derived phytochemicals with reported or proposed HAT- and/or HDAC-modulatory properties, focusing on parthenolide, anacardic acid, formononetin, plumbagin, and allicin and its derivatives, including S-allylmercaptocysteine (SAMC). The available evidence indicates that these compounds can influence epigenetic processes through distinct, pleiotropic, mechanisms, potentially affecting cellular proliferation, apoptosis, differentiation, and responses to anticancer treatment. Collectively, these findings support the further investigation of cryptic plant-derived HAT/HDAC modulators as candidate epigenetic adjuvants, while underscoring the need for rigorous mechanistic validation, pharmacokinetic characterization, and translational assessment.